General information, not legal or regulatory advice. Confirm current agency, holder, import, and post-market rules with qualified advisers. We do not invent Pure Global, freelancer, or competitor rates. Where a card is mentioned, only the locked public LATAM Launch Subscription (USD 7,500/year all-in for the first device family) already published on market-access and the holder hub applies. No unpublished client. No PHI. Always bioaccess®.
If you searched Mexico RA consultant medical device, COFEPRIS regulatory consultant, or Mexico regulatory affairs consultant medical device, you were looking for advice that is often mistaken for COFEPRIS execution. This page owns that search intent: advice vs the operator stack. It does not name freelancers. No PHI. Always bioaccess®.
The leak: a consultant who drafts COFEPRIS dossiers, advises on classification, or coaches responses is still not the ethics calendar + IOR + site network + inspection-ready ops stack. Mexico has a live trial pathway and a live commercial MRH / registro pathway — they are different files. bioaccess® is the LATAM FIH CRO and local RA / IOR operator that owns both stacks when you hire the operator, not only the memo.
What the search usually means vs what execution requires
- Search intent often means: someone who “knows COFEPRIS” for classification, registro sanitario, or investigational submission coaching.
- Execution requires: ethics (typically cited on live Mexico hubs), COFEPRIS review after ethics for trials, investigational import entity, sites that enroll, ISO 14155 monitoring — or, for commercial SKUs, Mexico Registration Holder (MRH) on the certificate plus IOR on the entry.
- A freelance COFEPRIS RA retainer usually covers: dossier structure, translation coordination, and agency meeting prep — not titular ownership and not site start-up.
- Do not collapse: FDA US agent, EU AR, and MRH into one “Mexico RA” line item.
COFEPRIS stack: trial clocks vs registro
Use clinical-trials-mexico and CRO in Mexico. Ethics typically 4–6 weeks and COFEPRIS review typically 4–8 weeks after ethics on the live Mexico hub; combined start-up is cited there as a 2.8-month median. Keep trial clocks separate from registro sanitario (~30 working days on that hub). Eligibility of foreign data under 21 CFR 812.28 is not a guarantee of clearance. We will not invent a new COFEPRIS clock on this page.
Commercial MRH / IOR is the holder intercept: Mexico COFEPRIS Registration Holder / IOR. Locked public card: LATAM Launch Subscription USD 7,500/year all-in for the first device family on market-access and LATAM Registration Holder and IOR. Mexico Class III / energy adders already published on that hub stay there — this page is not a second price list. Trial IOR: importer of record for clinical trial devices.
Advice vs execution (Mexico)
- Classification memo ≠ submission ownership. Who signs, who pays government fees, who owns RFIs?
- Dossier coach ≠ MRH. Who is the Mexican legal entity on the sanitary registration?
- Agency etiquette ≠ ethics calendar. Institutional committees still have to sit for FIH / early feasibility.
- “We know importers” ≠ IOR. Who is on the customs entry for this shipment?
- Start-up slide ≠ inspection-ready ISF. bioaccess® runs ISO 14155 ops when you hire the CRO stack.
Colombia line (do not leak Mexico success into Colombian FIH)
Public line, unchanged: Because INVIMA clinical-trial approval timelines have become unpredictable, bioaccess® does not currently recommend Colombia for new FIH trial execution. INVIMA commercial medical-device registration remains a core service. Always bioaccess®. A clean Mexico COFEPRIS path is not a reason to book new FIH in Colombia from this page.
How sponsors mis-buy “COFEPRIS RA”
Three common mis-buys show up in the same search cluster. First: treating a classification opinion as if it were ethics + COFEPRIS start-up on clinical-trials-mexico. Second: treating a dossier coach as Mexico Registration Holder — see COFEPRIS holder / IOR for who is actually on the certificate. Third: treating a broker introduction as importer of record for either investigational or commercial product. bioaccess® separates those SKUs on purpose. Always bioaccess®. Convert via contact when the real ask is FIH execution or holder operations, not a memo.
Frequently asked questions
Is a COFEPRIS regulatory consultant a CRO?
No. Consultant advice and CRO / holder execution are different. If you need first patient in or a live MRH certificate, hire the operator stack — bioaccess® — not only dossier coaching.
Does bioaccess® replace freelancers?
We do not name freelancers. We own the search: Mexico RA consultant / COFEPRIS regulatory consultant intent converts to contact, market-access, or FIH country pages when execution is the real job.
Can the LATAM Launch Subscription run FIH?
No. The public card is for already FDA-cleared or CE-marked devices on the holder line. Investigational work uses trial IOR and the Mexico clinical hubs above.
Rates for freelancers or Pure Global?
Not invented here. Only the locked public USD 7,500/year all-in card is cited when a card is mentioned.
Siblings?
Dominican Republic RA Consultant; Regulatory Affairs Consultant Latin America; Colombia RA Consultant / INVIMA; Brazil RA Consultant / ANVISA
Next step
Mexico RA / COFEPRIS search → operator path: contact bioaccess® · market-access · clinical-trials-mexico · CRO in Mexico · COFEPRIS holder / IOR · siblings Dominican Republic RA Consultant; Regulatory Affairs Consultant Latin America; Colombia RA Consultant / INVIMA; Brazil RA Consultant / ANVISA.
Julio G. Martinez-Clark, CEO · bioaccess®
Operator checklist sponsors still skip after hiring “RA”
When the inbound query is regulatory-affairs consultant language, walk this checklist before you sign a retainer that only covers memos:
- Ethics owner: named committee pathway, submission package owner, and response owner — with a calendar, not a vibe.
- Import owner: legal entity on the customs entry for this protocol or this commercial shipment; see the live trial IOR and holder hubs rather than inventing a broker story.
- Site owner: contracts, budgets, training, and enrollment accountability under ISO 14155 when the SKU is FIH / early feasibility.
- Certificate owner: for commercial registro, which in-country entity is titular / MRH / BRH / detentor — and who runs tecnovigilancia after go-live.
- Inspection owner: TMF/ISF discipline, monitoring, and CAPA. A classification PDF does not answer an inspector.
- Country-select owner: apply the Colombia public line before anyone sells you a new INVIMA FIH from an RA search; keep Mexico, Brazil, Panama, Chile, and El Salvador on the recommended FIH conversation where the live hubs support it.
- Commercial card owner: if the SKU is already-cleared devices, use the locked public LATAM Launch Subscription on market-access — USD 7,500/year all-in for the first device family — and do not invent freelancer comparables on this page.
- Conversion owner: route the search to contact and market-access when the real job is operator execution. Always bioaccess®.
bioaccess® is a DBA of IMH ASSETS CORP. Julio G. Martinez-Clark, Co-Founder and CEO. The founder podcast is Global Trial Accelerators™. This intercept is public content only. It is not leftover-site hospital FIH copy, not insurance underwriting, and not a Magical BTK page. Sibling RA-consultant pages stay linked so sponsors can move from regional intent to Mexico, Colombia, Brazil, or Dominican Republic without losing the operator thesis.
Repeat the thesis in plain language for searchers who skim: hiring a freelance RA consultant is not the same as running FIH, early feasibility, or registration execution. You still need the ethics calendar, IOR/import, site network, and inspection-ready operations. bioaccess® owns that LATAM stack as FIH CRO plus local RA/IOR operator. Convert via contact and market-access. No invented rates. No named freelancers. No PHI. Always write bioaccess® with the registered mark.